Okyo Pharma Ltd Stock Analysis
| OKYO Stock | USD 1.04 0.01 0.95% |
OKYO Pharma Ltd is overvalued with Real Value of 0.9 and Hype Value of 1.01. The main objective of OKYO Pharma stock analysis is to determine its intrinsic value, which is an estimate of what OKYO Pharma Ltd is worth, separate from its market price. There are two main types of OKYO Pharma's stock analysis: fundamental analysis and technical analysis.
The OKYO Pharma stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. OKYO Pharma is usually not traded on Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day. OKYO Stock trading window is adjusted to America/New York timezone.
OKYO |
OKYO Stock Analysis Notes
About 28.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 0.57. OKYO Pharma had not issued any dividends in recent years. OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom. Okyo Pharma is traded on NASDAQ Exchange in the United States. To find out more about OKYO Pharma Ltd contact Gary Jacob at 44 20 7495 2379 or learn more at https://okyopharma.com.OKYO Pharma Investment Alerts
| OKYO Pharma generated a negative expected return over the last 90 days | |
| OKYO Pharma has some characteristics of a very speculative penny stock | |
| OKYO Pharma has high historical volatility and very poor performance | |
| OKYO Pharma has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (16.8 M) with loss before overhead, payroll, taxes, and interest of (3.6 M). | |
| OKYO Pharma Ltd currently holds about 2.06 M in cash with (9.49 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.1. | |
| OKYO Pharma has a frail financial position based on the latest SEC disclosures | |
| Roughly 28.0% of the company outstanding shares are owned by corporate insiders |
OKYO Pharma Upcoming and Recent Events
Earnings reports are used by OKYO Pharma to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period..
| 21st of August 2023 Upcoming Quarterly Report | View | |
| 31st of March 2023 Next Fiscal Quarter End | View |
OKYO Stock Institutional Investors
| Shares | Barclays Plc | 2024-06-30 | 961 K | Citadel Advisors Llc | 2024-09-30 | 14.9 K | Hpm Partners Llc | 2024-06-30 | 12.8 K | Geode Capital Management, Llc | 2024-09-30 | 12.1 K | Hsbc Holdings Plc | 2024-06-30 | 11.9 K | Susquehanna International Group, Llp | 2024-06-30 | 11.1 K | Ubs Group Ag | 2024-06-30 | 1.9 K | Continuum Advisory, Llc | 2024-06-30 | 50.0 |
OKYO Market Capitalization
The company currently falls under 'Micro-Cap' category with a current market capitalization of 36.54 M.OKYO Profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.01) | (0.01) | |
| Return On Assets | (0.01) | (0.01) |
Management Efficiency
OKYO Pharma has return on total asset (ROA) of (2.9187) % which means that it has lost $2.9187 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (29.6851) %, meaning that it created substantial loss on money invested by shareholders. OKYO Pharma's management efficiency ratios could be used to measure how well OKYO Pharma manages its routine affairs as well as how well it operates its assets and liabilities. As of the 27th of November 2024, Return On Equity is likely to grow to 0, while Return On Tangible Assets are likely to drop (0.01). As of the 27th of November 2024, Intangible Assets is likely to grow to about 8.9 M, while Total Assets are likely to drop about 1.5 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (0.20) | (0.19) | |
| Net Current Asset Value | 42.89 | 38.12 | |
| Tangible Book Value Per Share | (0.20) | (0.19) | |
| Enterprise Value Over EBITDA | -2.7 K | -2.6 K | |
| Price Book Value Ratio | (7.34) | (7.70) | |
| Enterprise Value Multiple | -2.7 K | -2.6 K | |
| Price Fair Value | (7.34) | (7.70) | |
| Enterprise Value | 42.3 M | 40.2 M |
The strategic vision of OKYO Pharma Ltd management plays a critical role in its financial performance. By evaluating this vision, we provide insights into the stock's growth potential.
Beta (3.36) | Return On Assets (2.92) | Return On Equity (29.69) |
Technical Drivers
As of the 27th of November, OKYO Pharma holds the Market Risk Adjusted Performance of 0.4172, risk adjusted performance of 0.0309, and Semi Deviation of 4.07. In connection with fundamental indicators, the technical analysis model allows you to check available technical drivers of OKYO Pharma, as well as the relationship between them.OKYO Pharma Price Movement Analysis
The output start index for this execution was thirteen with a total number of output elements of fourty-eight. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. OKYO Pharma middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for OKYO Pharma. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
OKYO Pharma Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific OKYO Pharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on OKYO Pharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases OKYO Pharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Denoyer Bernard over six months ago Disposition of 1000000 shares by Denoyer Bernard of OKYO Pharma at 0.1045 subject to Rule 16b-3 | ||
Cerrone Gabriele M over a year ago Acquisition or disposition of OKYO Pharma securities by Cerrone Gabriele M | ||
Brancaccio John P over a year ago Purchase by Brancaccio John P of 16670 shares of OKYO Pharma |
OKYO Pharma Outstanding Bonds
OKYO Pharma issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. OKYO Pharma uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most OKYO bonds can be classified according to their maturity, which is the date when OKYO Pharma Ltd has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
OKYO Pharma Predictive Daily Indicators
OKYO Pharma intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of OKYO Pharma stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
OKYO Pharma Forecast Models
OKYO Pharma's time-series forecasting models are one of many OKYO Pharma's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary OKYO Pharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About OKYO Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how OKYO Pharma prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling OKYO shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as OKYO Pharma. By using and applying OKYO Stock analysis, traders can create a robust methodology for identifying OKYO entry and exit points for their positions.
| Last Reported | Projected for Next Year |
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding OKYO Pharma to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Funds Screener Now
Funds ScreenerFind actively-traded funds from around the world traded on over 30 global exchanges |
| All Next | Launch Module |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in OKYO Pharma Ltd. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of OKYO Pharma. If investors know OKYO will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about OKYO Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.57) | Return On Assets (2.92) | Return On Equity (29.69) |
The market value of OKYO Pharma is measured differently than its book value, which is the value of OKYO that is recorded on the company's balance sheet. Investors also form their own opinion of OKYO Pharma's value that differs from its market value or its book value, called intrinsic value, which is OKYO Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because OKYO Pharma's market value can be influenced by many factors that don't directly affect OKYO Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between OKYO Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if OKYO Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, OKYO Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.